Here’s a startling fact: nearly 1 in 10 adolescents and young adults (AYAs) diagnosed with early-stage cancer will later face metastatic disease, and their survival odds are often worse than those who are diagnosed with metastatic cancer from the start. But here’s where it gets even more alarming: new research reveals that for most cancer types, patients who experience metastatic recurrence fare significantly worse than those whose cancer is metastatic at initial diagnosis. This finding, published in JAMA Oncology (https://jamanetwork.com/journals/jamaoncology/article-abstract/2841867), sheds light on a critical yet overlooked challenge in cancer care for younger populations.
"These results underscore the immense burden of metastatic recurrence in AYAs and the urgent need for personalized survivorship plans," explains senior study author Theresa Keegan, PhD, MS, Professor of Medicine at UC Davis Health Medical Center. "By understanding these patterns, we can better identify disparities and assess the effectiveness of our efforts to prevent, detect, and treat both early and advanced cancers."
How Did Researchers Uncover This?
The study team conducted a retrospective analysis of AYAs aged 15 to 39 diagnosed with nonmetastatic cancer between 2006 and 2018. Drawing from the California Cancer Registry, they examined data from 48,406 patients with melanoma, sarcoma, breast, cervical, colorectal, testicular, and thyroid cancers. Here’s what they found:
- Prevalence of Metastatic Disease: 9.2% of patients had metastatic cancer at diagnosis, while 9.5% developed metastatic recurrence. Colorectal cancer and sarcoma had the highest rates of metastatic disease.
- High-Risk Cancers: Sarcoma and colorectal cancer patients faced the highest 5-year cumulative incidence of metastatic recurrence—24.5% and 21.8%, respectively.
- Stage Matters: Metastatic recurrence was more common in higher-stage cancers at diagnosis. For instance, stage III cervical cancer patients had a staggering 41.7% cumulative incidence of recurrence.
- Trends Over Time: While metastatic recurrence rates for cervical cancer increased (from 12.7% in 2006–2009 to 20.4% in 2015–2018), colorectal cancer rates decreased (from 24.4% to 19.2% over the same period).
- Survival Disparities: Patients with metastatic recurrence had poorer survival outcomes compared to those with de novo metastatic disease for all cancer types except testicular and thyroid cancers. For example, breast cancer patients with recurrence had a hazard ratio of 2.87, while cervical cancer patients had a ratio of 2.10.
And this is the part most people miss: As treatments improve and survival rates rise, young cancer patients face unique long-term challenges, including the heightened risk of metastatic recurrence. "Our study deepens our understanding of survivorship and the impact of recurrence," notes lead author Ann Brunson, MS, Research Analyst at UC Davis Comprehensive Cancer Center. "By leveraging statewide data, we’re uncovering trends that can shape future research and care strategies."
Controversial Question: Should cancer care for AYAs prioritize early detection of recurrence over traditional survivorship programs? Or is the focus on initial treatment still the best approach? Let us know your thoughts in the comments.
For full disclosures of the study authors, visit JAMA Oncology (https://jamanetwork.com/journals/jamaoncology/article-abstract/2841867). The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.
